RxDoctor Payments Data

Raul Correa, MD

Neuromusculoskeletal Medicine, Sports Medicine · Bradenton, FLNPI 1417955840

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $423 of the $517 with a category attached, or 81.9%. 11 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 26.3% of the total. Reporting peaked in 2021 at $324 and has fallen 93.7% since, to $20 in 2025.

$517in general payments, 2019–2025

Across 16 payments — averaging $32.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$136
  • Novartis$101
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$94
  • AbbVie$41
  • Johnson & Johnson$35
  • Nestle Healthcare Nutrition Inc.$28
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$42382%
  • Education$9418%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromusculoskeletal medicine, sports medicine providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$254,712
Medicare patients
98
Services billed
2,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$30,548
OzempicSemaglutide31$28,933
MounjaroTirzepatide15$24,778
XareltoRivaroxaban22$20,052
NamzaricMemantine Hcl/Donepezil Hcl31$15,900
LinzessLinaclotide20$14,976
FarxigaDapagliflozin Propanediol25$14,331
JanuviaSitagliptin Phosphate22$13,451
SymbicortBudesonide/Formoterol Fumarate12$2,888
Novolin N FlexpenInsulin Nph Human Isophane15$2,514
Potassium Chloride105$2,509
Levothyroxine Sodium230$2,340
Alprazolam155$1,983
Valsartan39$1,793
Atorvastatin Calcium178$1,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Linzess$41$30,87651 claims
Johnson & JohnsonXarelto$35$20,05222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine, sports medicine providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other neuromusculoskeletal medicine, sports medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →